Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway

Oncotarget

Volumn 7, Issue 3, 2016, Pages 3533-3547

  Tang, Ning ^a   Shi, Lei ^a   Yu, Zhenlong ^a,b   Dong, Peipei ^a   Wang, Chao ^a   Huo, Xiaokui ^a   Zhang, Baojing ^a   Huang, Shanshan ^a   Deng, Sa ^a   Liu, Kexin ^a   Ma, Tonghui ^a   Wang, Xiaobo ^b   Wu, Lijun ^b   Ma, Xiao Chi ^a,b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b The 210th Hospital of PLA   (China)

Author keywords

Angiogenesis; Aortic ring; Gamabufotalin; Vascular endothelial growth factor (VEGF); Vascular endothelial growth factor receptor 2 (VEGFR 2)

Indexed keywords

ADENOSINE TRIPHOSPHATE; BUFADIENOLIDE DERIVATIVE; GAMABUFOTALIN; MATRIGEL; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; SMALL INTERFERING RNA; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; BINDING SITE; CAPILLARY DENSITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; APOPTOSIS; C57BL MOUSE; CELL CULTURE; CELL MOTION; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOPRECIPITATION; LUNG NEOPLASMS; METABOLISM; MOLECULAR MODEL; NUDE MOUSE; PATHOLOGY; VASCULAR ENDOTHELIUM; VASCULARIZATION; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; AORTA; APOPTOSIS; BLOTTING, WESTERN; BUFANOLIDES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOPRECIPITATION; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, NUDE; MODELS, MOLECULAR; NEOVASCULARIZATION, PHYSIOLOGIC; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; WOUND HEALING;

EID: 84962318195     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6514     Document Type: Article

References (48)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature medicine. 1995; 1:27-31.
2. Carmeliet P and Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407:249-257.
3. Dvorak HF. Angiogenesis: update 2005. Journal of thrombosis and haemostasis: JTH. 2005; 3:1835-1842.
4. Ivy SP, Wick JY and Kaufman BM. An overview of smallmolecule inhibitors of VEGFR signaling. Nature reviews Clinical oncology. 2009; 6:569-579.
5. Zhao Y and Adjei AA. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. The oncologist. 2015; 20:660-673.
6. Turner HE, Harris AL, Melmed S and Wass JA. Angiogenesis in endocrine tumors. Endocrine reviews. 2003; 24:600-632.
7. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nature reviews Drug discovery. 2007; 6:273-286.
8. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer letters. 2012; 320:130-137.
9. Ambasta RK, Sharma A and Kumar P. Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy. Vascular cell. 2011; 3:26.
10. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM and Dvorak HF. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer metastasis reviews. 1993; 12:303-324.
11. Stefanini MO, Wu FT, Mac Gabhann F and Popel AS. A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC systems biology. 2008; 2:77.
12. Romon R, Adriaenssens E, Lagadec C, Germain E, Hondermarck H and Le Bourhis X. Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways. Molecular cancer. 2010; 9:157.
13. Greenberg S and Rugo HS. Triple-negative breast cancer: role of antiangiogenic agents. Cancer journal. 2010; 16:33-38.
14. Delli Carpini J, Karam AK and Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis. 2010; 13:43-58.
15. Otrock ZK, Makarem JA and Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review. Blood cells, molecules & diseases. 2007; 38:258-268.
16. Ferrara N, Gerber HP and LeCouter J. The biology of VEGF and its receptors. Nature medicine. 2003; 9:669-676.
17. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine reviews. 2004; 25:581-611.
18. Xia Y, Song X, Li D, Ye T, Xu Y, Lin H, Meng N, Li G, Deng S, Zhang S, Liu L, Zhu Y, Zeng J, Lei Q, Pan Y, Wei Y, et al. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models. Scientific reports. 2014; 4:6031.
19. Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA and de Vos AM. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell. 1997; 91:695-704.
20. Lu D, Kussie P, Pytowski B, Persaud K, Bohlen P, Witte L and Zhu Z. Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies. The Journal of biological chemistry. 2000; 275:14321-14330.
21. van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, Gallagher WM and Byrne AT. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. Drug discovery today. 2011; 16:219-228.
22. Kranenburg O, Gebbink MF and Voest EE. Stimulation of angiogenesis by Ras proteins. Biochimica et biophysica acta. 2004; 1654:23-37.
23. Meadows KN, Bryant P, Vincent PA and Pumiglia KM. Activated Ras induces a proangiogenic phenotype in primary endothelial cells. Oncogene. 2004; 23:192-200.
24. Meadows KN, Bryant P and Pumiglia K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. The Journal of biological chemistry. 2001; 276:49289-49298.
25. Li M, Wu S, Liu Z, Zhang W, Xu J, Wang Y, Liu J, Zhang D, Tian H, Li Y and Ye W. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway. Biochemical pharmacology. 2012; 83:1251-1260.
26. May BH, Lu C, Bennett L, Hugel HM and Xue CC. Evaluating the traditional Chinese literature for herbal formulae and individual herbs used for age-related dementia and memory impairment. Biogerontology. 2012; 13:299-312.
27. Xin XL, Liu J, Ma XC, Wei Q, Lv L, Wang CY, Yao JH and Cui J. Preparative separation of four major bufadienolides from the Chinese traditional medicine, Chansu, using high-speed counter-current chromatography. Natural product communications. 2010; 5:1031-1034.
28. Ma XC, Xin X, Zhang BJ, Deng S, Yao JH, Wang CY, Cui J, Tian Y and Liu KX. Efficient isolation and purification of five products from microbial biotransformation of cinobufagin by high-speed counter-current chromatography. Journal of separation science. 2010; 33:2272-2277.
29. Kamano Y, Kotake A, Hashima H, Inoue M, Morita H, Takeya K, Itokawa H, Nandachi N, Segawa T, Yukita A, Saitou K, Katsuyama M and Pettit GR. Structure-cytotoxic activity relationship for the toad poison bufadienolides. Bioorganic & medicinal chemistry. 1998; 6:1103-1115.
30. Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP and Pan BR. Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World journal of gastroenterology. 2008; 14:5210-5216.
31. Qi F, Li A, Inagaki Y, Kokudo N, Tamura S, Nakata M and Tang W. Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. International immunopharmacology. 2011; 11:342-349.
32. Li D, Qu X, Hou K, Zhang Y, Dong Q, Teng Y, Zhang J and Liu Y. PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anti-cancer drugs. 2009; 20:59-64.
33. Ko WS, Park TY, Park C, Kim YH, Yoon HJ, Lee SY, Hong SH, Choi BT, Lee YT and Choi YH. Induction of apoptosis by Chan Su, a traditional Chinese medicine, in human bladder carcinoma T24 cells. Oncology reports. 2005; 14:475-480.
34. Yu Z, Guo W, Ma X, Zhang B, Dong P, Huang L, Wang X, Wang C, Huo X, Yu W, Yi C, Xiao Y, Yang W, Qin Y, Yuan Y, Meng S, et al. Gamabufotalin, a bufadienolide compound from toad venom, suppresses COX-2 expression through targeting IKKbeta/NF-kappaB signaling pathway in lung cancer cells. Molecular cancer. 2014; 13:203.
35. Xu JL, Lai R, Kinoshita T, Nakashima N and Nagasaka T. Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. Journal of clinical pathology. 2002; 55:530-534.
36. Abu-Ghazaleh R, Kabir J, Jia H, Lobo M and Zachary I. Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells. The Biochemical journal. 2001; 360:255-264.
37. Patan S. Vasculogenesis and angiogenesis. Cancer treatment and research. 2004; 117:3-32.
38. Saunders WB, Bohnsack BL, Faske JB, Anthis NJ, Bayless KJ, Hirschi KK and Davis GE. Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. The Journal of cell biology. 2006; 175:179-191.
39. Uchida C and Haas TL. Evolving strategies in manipulating VEGF/VEGFR signaling for the promotion of angiogenesis in ischemic muscle. Current pharmaceutical design. 2009; 15:411-421.
40. Guo S, Colbert LS, Fuller M, Zhang Y and Gonzalez-Perez RR. Vascular endothelial growth factor receptor-2 in breast cancer. Biochimica et biophysica acta. 2010; 1806:108-121.
41. Carmeliet P, Lampugnani MG, Moons L, Breviario F, Compernolle V, Bono F, Balconi G, Spagnuolo R, Oosthuyse B, Dewerchin M, Zanetti A, Angellilo A, Mattot V, Nuyens D, Lutgens E, Clotman F, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell. 1999; 98:147-157.
42. Cook KM and Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA: a cancer journal for clinicians. 2010; 60:222-243.
43. Zhang S, Cao Z, Tian H, Shen G, Ma Y, Xie H, Liu Y, Zhao C, Deng S, Yang Y, Zheng R, Li W, Zhang N, Liu S, Wang W, Dai L, et al. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17:4439-4450.
44. Sandur SK, Ichikawa H, Sethi G, Ahn KS and Aggarwal BB. Plumbagin (5-hydroxy-2-methyl-1, 4-naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. The Journal of biological chemistry. 2006; 281:17023-17033.
45. Miyazaki Y, Matsunaga S, Tang J, Maeda Y, Nakano M, Philippe RJ, Shibahara M, Liu W, Sato H, Wang L and Nolte RT. Novel 4-amino-furo[2, 3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorganic & medicinal chemistry letters. 2005; 15:2203-2207.
46. Chen J, Sheng C-Q, Zhang W-N, Zheng C-H, Zhou Y-J, Li Y-W and Zhu J. Study of Properties of VEGFR2 Active Site and Binding Mode of VEGFR2 and Its Inhibitors. Acta Chimica Sinica. 2007; 65, 2007(No. 6):6.
47. Shi L, Fisslthaler B, Zippel N, Fromel T, Hu J, Elgheznawy A, Heide H, Popp R and Fleming I. MicroRNA-223 antagonizes angiogenesis by targeting beta1 integrin and preventing growth factor signaling in endothelial cells. Circulation research. 2013; 113:1320-1330.
48. Agarwal C, Singh RP and Agarwal R. Grape seed extract induces apoptotic death of human prostate carcinoma DU145 cells via caspases activation accompanied by dissipation of mitochondrial membrane potential and cytochrome c release. Carcinogenesis. 2002; 23:1869-1876.